Skip to content Skip to sidebar Skip to footer
Menu
Menu
Newsletter
Menu
Newsletter
Ramelius
Gold Stocks
Ramelius Resources (ASX:RMS) Rallies After A$250m Capital Return Program: Should You Buy the Gold Miner?
Ramelius Resources (ASX: RMS) jumped to an intraday high of A$3.71 this week before closing at A$3.57, up 5.6%, after announcing a A$250 million share buyback and doubling its minimum dividend to 2 cents per share. For gold investors, this signals management believes the stock is cheap and cash generation can reward shareholders while funding…
December 11, 20250Comments
Orthocell
Healthcare Stocks
Orthocell (ASX:OCC) Surges 7% on First Hong Kong Sales: Is This Healthcare Stock a Buy as Asian Expansion Accelerates?
Orthocell (ASX: OCC) jumped 7% to A$1.09 on Wednesday after announcing its first commercial sales of Remplir in Hong Kong. The sales, made through distributor MontsMed, follow last month's first surgical case in the region and a strong debut at the Hong Kong Orthopaedic Association's 45th Annual Congress. For investors, this milestone shows the company…
December 11, 20250Comments
Moonlight
Gold Stocks
Moonlight Resources (ASX:ML8) Lists Tomorrow After A$10m IPO: Should You Buy This Gold and Critical Minerals Explorer?
Moonlight Resources (ASX: ML8) will make its ASX debut on 11 December 2025 after completing a A$10 million IPO at A$0.20 per share. The company is a gold and critical minerals explorer with a sizeable 5,200 square kilometre tenement portfolio spanning Queensland, Northern Territory, NSW, and Western Australia. What makes this listing worth watching is the…
December 10, 20250Comments
PWR Holdings
Tech Stocks
PWR Holdings Gets New Leadership: What It Means for Investors After a Tough FY25
PWR Holdings backs internal leader for next phase PWR Holdings (ASX: PWH) announced yesterday that Chief Financial Officer Sharyn Williams will become its next CEO and Managing Director, marking a significant leadership transition for the high-tech cooling solutions company. Williams, who joined as CFO in January 2025, will take over once a replacement is found,…
December 10, 20250Comments
Race Oncology
Biotech Stocks
Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?
Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at $2.83 per share, a 6% premium to its last close. For a small-cap biotech, that’s unusual; most need to offer discounts to attract funding. This premium placement shows investors are confident about the upcoming HARNESS-1…
December 10, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Investing in the Year of the Rat
2020, the Golden Year
Market trouble spots to avoid in 2020
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here